FAM181B

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, FAM181B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM181B data layer compared with 26 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher FAM181B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM181B expression acts as an unfavorable survival marker.

LGG are the cancer types where FAM181B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
LGGDFSMedianAll0.1610.753<.0016view →
Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

FAM181B–LGG (DFS)

Kaplan–Meier survival curve for FAM181B mutant vs wild-type samples in LGG.

Open the LGG breakdown →

Exploration